Recombinant Anti-Myelin Basic Protein antibody [12] (ab7349)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rat monoclonal [12] to Myelin Basic Protein
- Suitable for: WB, IHC-P
- Reacts with: Mouse, Rat, Human
Related conjugates and formulations
Overview
-
Product name
Anti-Myelin Basic Protein antibody [12]
See all Myelin Basic Protein primary antibodies -
Description
Rat monoclonal [12] to Myelin Basic Protein -
Host species
Rat -
Tested applications
Suitable for: WB, IHC-Pmore details -
Species reactivity
Reacts with: Mouse, Rat, Human -
Immunogen
Full length protein corresponding to Cow Myelin Basic Protein.
-
Epitope
Amino acids 82-87 (DENPVV). -
Positive control
- WB: Human cerebellum, Mouse brain tissue and Rat brain tissue. IHC-P: Human cerebellum tissue.
-
General notes
This product has switched from a hybridoma to recombinant production method on 08th November 2021.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. -
Storage buffer
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
Purity
Ion Exchange Chromatography -
Clonality
Monoclonal -
Clone number
12 -
Isotype
IgG2a -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab7349 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB | (2) |
1/1000.
|
IHC-P | (6) |
1/4000. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
|
Notes |
---|
WB
1/1000. |
IHC-P
1/4000. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
Target
-
Function
The classic group of MBP isoforms (isoform 4-isoform 14) are with PLP the most abundant protein components of the myelin membrane in the CNS. They have a role in both its formation and stabilization. The smaller isoforms might have an important role in remyelination of denuded axons in multiple sclerosis. The non-classic group of MBP isoforms (isoform 1-isoform 3/Golli-MBPs) may preferentially have a role in the early developing brain long before myelination, maybe as components of transcriptional complexes, and may also be involved in signaling pathways in T-cells and neural cells. Differential splicing events combined with optional post-translational modifications give a wide spectrum of isomers, with each of them potentially having a specialized function. Induces T-cell proliferation. -
Tissue specificity
MBP isoforms are found in both the central and the peripheral nervous system, whereas Golli-MBP isoforms are expressed in fetal thymus, spleen and spinal cord, as well as in cell lines derived from the immune system. -
Involvement in disease
Note=The reduction in the surface charge of citrullinated and/or methylated MBP could result in a weakened attachment to the myelin membrane. This mechanism could be operative in demyelinating diseases such as chronical multiple sclerosis (MS), and fulminating MS (Marburg disease). -
Sequence similarities
Belongs to the myelin basic protein family. -
Developmental stage
Expression begins abruptly in 14-16 week old fetuses. Even smaller isoforms seem to be produced during embryogenesis; some of these persisting in the adult. Isoform 4 expression is more evident at 16 weeks and its relative proportion declines thereafter. -
Post-translational
modificationsSeveral charge isomers of MBP; C1 (the most cationic, least modified, and most abundant form), C2, C3, C4, C5, C6, C7, C8-A and C8-B (the least cationic form); are produced as a result of optional PTM, such as phosphorylation, deamidation of glutamine or asparagine, arginine citrullination and methylation. C8-A and C8-B contain each two mass isoforms termed C8-A(H), C8-A(L), C8-B(H) and C8-B(L), (H) standing for higher and (L) for lower molecular weight. C3, C4 and C5 are phosphorylated. The ratio of methylated arginine residues decreases during aging, making the protein more cationic.
The N-terminal alanine is acetylated (isoform 3, isoform 4, isoform 5 and isoform 6).
Arg-241 was found to be 6% monomethylated and 60% symmetrically dimethylated. -
Cellular localization
Myelin membrane. Cytoplasmic side of myelin. - Information by UniProt
-
Database links
- Entrez Gene: 4155 Human
- Entrez Gene: 17196 Mouse
- Entrez Gene: 24547 Rat
- Omim: 159430 Human
- SwissProt: P02686 Human
- SwissProt: P04370 Mouse
- SwissProt: P02688 Rat
- Unigene: 551713 Human
see all -
Alternative names
- GDB antibody
- Golli MBP antibody
- Golli MBP; myelin basic protein antibody
see all
Images
-
Anti-Myelin Basic Protein antibody [12] (ab7349) at 1/5000 dilution + Human cerebellum tissue lysate at 10 µg
Secondary
Goat Anti-Rat IgG H&L (HRP) (ab205720) at 1/10000 dilution
Developed using the ECL technique.
Observed band size: 18.5 kDa why is the actual band size different from the predicted?
Exposure time: 1 secondThe molecular weight observed was in consistency with the literature (PMID: 9299539).
Blocking buffer: 5% NFDM/TBST.
-
All lanes : Anti-Myelin Basic Protein antibody [12] (ab7349) at 1/5000 dilution
Lane 1 : Mouse brain tissue lysate
Lane 2 : Rat brain tissue lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rat IgG H&L (HRP) (ab205720) at 1/10000 dilution
Observed band size: 14-21.5 kDa why is the actual band size different from the predicted?The molecular weight observed was in consistency with the literature (PMID: 9299539).
Blocking buffer: 5% NFDM/TBST.
Exposure time: Lane 1: 3 seconds; Lane 2: 1 second.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Myelin Basic Protein antibody [12] (ab7349)
Immunohistochemical analysis of paraffin-embedded Human cerebrum labeling Myelin Basic Protein with ab7349 at 1/4000 dilution (0.259 µg/ml) followed by a ready to use Goat Anti-Rabbit IgG H&L (HRP Polymer; ab214882). The section was incubated with ab7349 for 30 mins at room temperature. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin.
Heat mediated antigen retrieval with Citrate buffer (pH 6.0, epitope retrieval solution 1) for 20 mins.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Myelin Basic Protein antibody [12] (ab7349)
Immunohistochemical analysis of paraffin-embedded Human cerebrum labeling Myelin Basic Protein with ab7349 at 1/4000 dilution (0.259 µg/ml) followed by a ready to use Goat Anti-Rabbit IgG H&L (HRP Polymer; ab214882). The section was incubated with ab7349 for 30 mins at room temperature. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with DAPI.
Heat mediated antigen retrieval with Citrate buffer (pH 6.0, epitope retrieval solution 1) for 20 mins.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (204)
ab7349 has been referenced in 204 publications.
- Wu S et al. Retinoic acid increases phagocytosis of myelin by macrophages. J Cell Physiol 236:3929-3945 (2021). PubMed: 33165955
- Melero-Jerez C et al. Myeloid-derived suppressor cells support remyelination in a murine model of multiple sclerosis by promoting oligodendrocyte precursor cell survival, proliferation, and differentiation. Glia 69:905-924 (2021). PubMed: 33217041
- Iacono D et al. Reduction of pTau and APP levels in mammalian brain after low-dose radiation. Sci Rep 11:2215 (2021). PubMed: 33500491
- Maas DA et al. Antioxidant treatment ameliorates prefrontal hypomyelination and cognitive deficits in a rat model of schizophrenia. Neuropsychopharmacology 46:1161-1171 (2021). PubMed: 33564104
- Boutary S et al. Squalenoyl siRNA PMP22 nanoparticles are effective in treating mouse models of Charcot-Marie-Tooth disease type 1 A. Commun Biol 4:317 (2021). PubMed: 33750896